SkyCell AG is thrilled to announce that it has successfully raised CHF 59 million in funding, paving the way for the next phase of its revolutionary impact on the global pharmaceutical logistics sector. Based in Switzerland, SkyCell is renowned for its cutting-edge temperature-controlled hybrid containers that utilize transformative data-driven technology to optimize the pharmaceutical supply chain while minimizing the risk of damage to valuable cargo. The newly acquired capital will be instrumental in enhancing the capabilities of SkyCell鈥檚 innovative supply chain operating system, SkyMind, which boasts an industry-leading temperature excursion rate of less than 0.05%. This robust data analytics platform not only increases operational efficiency but also significantly contributes to sustainability by reducing CO2 emissions. With a commitment to sustainability at its core, SkyCell鈥檚 reusable hybrid containers cut CO2 pollution by up to 50% while simultaneously championing waste reduction practices. As the company focuses on scaling its solutions and expanding its market presence, it aims to empower pharmaceutical companies to meet the challenges of a rapidly changing climate while ensuring secure and safe transportation of critical medicine. We invite you to join us on this transformative journey as we redefine the parameters of the pharmaceutical supply chain through relentless innovation and sustainability, further solidifying our commitment to a greener, more efficient future in pharma logistics. Together, let鈥檚 carve out a new path towards progress.
#SkyCell #PharmaLogistics #TemperatureControlledContainers #InnovationInPharma #SustainabilityInTheSupplyChain #SafeSecureSustainable
